Ambuja Cements Limited

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ULTRACEMCO.BO has a market cap of 3.3T. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ULTRACEMCO.BO trades at ₹11,051.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ULTRACEMCO.BO's P/E ratio is 42.52. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ULTRACEMCO.BO's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to ULTRACEMCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ULTRACEMCO.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ULTRACEMCO.NS has a market cap of 3.3T. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ULTRACEMCO.NS trades at ₹11,049.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ULTRACEMCO.NS's P/E ratio is 42.51. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ULTRACEMCO.NS's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to ULTRACEMCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ULTRACEMCO.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, GRASIM.BO has a market cap of 1.8T. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while GRASIM.BO trades at ₹2,627.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas GRASIM.BO's P/E ratio is 41.23. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to GRASIM.BO's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to GRASIM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check GRASIM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, GRASIM.NS has a market cap of 1.8T. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while GRASIM.NS trades at ₹2,628.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas GRASIM.NS's P/E ratio is 39.39. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to GRASIM.NS's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to GRASIM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check GRASIM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, AMBUJACEM.BO has a market cap of 1T. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while AMBUJACEM.BO trades at ₹408.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas AMBUJACEM.BO's P/E ratio is 27.30. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to AMBUJACEM.BO's ROE of +0.06%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to AMBUJACEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check AMBUJACEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SHREECEM.BO has a market cap of 856.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SHREECEM.BO trades at ₹23,726.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SHREECEM.BO's P/E ratio is 49.83. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SHREECEM.BO's ROE of +0.08%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SHREECEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SHREECEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SHREECEM.NS has a market cap of 855.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SHREECEM.NS trades at ₹23,705.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SHREECEM.NS's P/E ratio is 47.72. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SHREECEM.NS's ROE of +0.08%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SHREECEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SHREECEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, JKCEMENT.BO has a market cap of 393.2B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while JKCEMENT.BO trades at ₹5,088.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas JKCEMENT.BO's P/E ratio is 38.50. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to JKCEMENT.BO's ROE of +0.17%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to JKCEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check JKCEMENT.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, JKCEMENT.NS has a market cap of 393B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while JKCEMENT.NS trades at ₹5,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas JKCEMENT.NS's P/E ratio is 38.51. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to JKCEMENT.NS's ROE of +0.17%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to JKCEMENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check JKCEMENT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, DALBHARAT.NS has a market cap of 348.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while DALBHARAT.NS trades at ₹1,857.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas DALBHARAT.NS's P/E ratio is 29.34. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to DALBHARAT.NS's ROE of +0.07%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to DALBHARAT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check DALBHARAT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, DALBHARAT.BO has a market cap of 347.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while DALBHARAT.BO trades at ₹1,855.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas DALBHARAT.BO's P/E ratio is 29.36. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to DALBHARAT.BO's ROE of +0.07%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to DALBHARAT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check DALBHARAT.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ACC.NS has a market cap of 246.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ACC.NS trades at ₹1,314.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ACC.NS's P/E ratio is 9.11. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ACC.NS's ROE of +0.14%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ACC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ACC.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ACC.BO has a market cap of 246.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ACC.BO trades at ₹1,314.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ACC.BO's P/E ratio is 9.34. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ACC.BO's ROE of +0.14%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ACC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ACC.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, RAMCOCEM.BO has a market cap of 215.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while RAMCOCEM.BO trades at ₹911.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas RAMCOCEM.BO's P/E ratio is 37.43. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to RAMCOCEM.BO's ROE of +0.08%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to RAMCOCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check RAMCOCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, RAMCOCEM.NS has a market cap of 215.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while RAMCOCEM.NS trades at ₹910.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas RAMCOCEM.NS's P/E ratio is 37.44. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to RAMCOCEM.NS's ROE of +0.08%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to RAMCOCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check RAMCOCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, JSWCEMENT.NS has a market cap of 153.2B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while JSWCEMENT.NS trades at ₹114.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas JSWCEMENT.NS's P/E ratio is -14.01. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to JSWCEMENT.NS's ROE of -0.26%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to JSWCEMENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check JSWCEMENT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, JSWCEMENT.BO has a market cap of 153B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while JSWCEMENT.BO trades at ₹114.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas JSWCEMENT.BO's P/E ratio is -13.99. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to JSWCEMENT.BO's ROE of -0.26%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to JSWCEMENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check JSWCEMENT.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, INDIACEM.BO has a market cap of 110.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while INDIACEM.BO trades at ₹356.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas INDIACEM.BO's P/E ratio is -100.89. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to INDIACEM.BO's ROE of -0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to INDIACEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check INDIACEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, INDIACEM.NS has a market cap of 110.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while INDIACEM.NS trades at ₹356.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas INDIACEM.NS's P/E ratio is -100.85. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to INDIACEM.NS's ROE of -0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to INDIACEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check INDIACEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NUVOCO.NS has a market cap of 107B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NUVOCO.NS trades at ₹299.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NUVOCO.NS's P/E ratio is 27.81. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NUVOCO.NS's ROE of +0.04%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NUVOCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NUVOCO.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NUVOCO.BO has a market cap of 106.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NUVOCO.BO trades at ₹299.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NUVOCO.BO's P/E ratio is 27.79. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NUVOCO.BO's ROE of +0.04%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NUVOCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NUVOCO.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, STARCEMENT.NS has a market cap of 83.6B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while STARCEMENT.NS trades at ₹206.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas STARCEMENT.NS's P/E ratio is 22.67. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to STARCEMENT.NS's ROE of +0.13%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to STARCEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check STARCEMENT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, STARCEMENT.BO has a market cap of 83.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while STARCEMENT.BO trades at ₹206.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas STARCEMENT.BO's P/E ratio is 22.61. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to STARCEMENT.BO's ROE of +0.13%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to STARCEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check STARCEMENT.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, JKLAKSHMI.NS has a market cap of 72.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while JKLAKSHMI.NS trades at ₹586.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas JKLAKSHMI.NS's P/E ratio is 15.69. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to JKLAKSHMI.NS's ROE of +0.13%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to JKLAKSHMI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check JKLAKSHMI.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, JKLAKSHMI.BO has a market cap of 72.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while JKLAKSHMI.BO trades at ₹586.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas JKLAKSHMI.BO's P/E ratio is 15.68. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to JKLAKSHMI.BO's ROE of +0.13%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to JKLAKSHMI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check JKLAKSHMI.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BIRLACORPN.NS has a market cap of 67.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BIRLACORPN.NS trades at ₹871.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BIRLACORPN.NS's P/E ratio is 12.93. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BIRLACORPN.NS's ROE of +0.07%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BIRLACORPN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BIRLACORPN.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BIRLACORPN.BO has a market cap of 67.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BIRLACORPN.BO trades at ₹871.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BIRLACORPN.BO's P/E ratio is 12.92. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BIRLACORPN.BO's ROE of +0.07%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BIRLACORPN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BIRLACORPN.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, PRSMJOHNSN.BO has a market cap of 63.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while PRSMJOHNSN.BO trades at ₹125.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas PRSMJOHNSN.BO's P/E ratio is 32.35. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to PRSMJOHNSN.BO's ROE of +0.12%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to PRSMJOHNSN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check PRSMJOHNSN.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, PRSMJOHNSN.NS has a market cap of 63.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while PRSMJOHNSN.NS trades at ₹125.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas PRSMJOHNSN.NS's P/E ratio is 32.33. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to PRSMJOHNSN.NS's ROE of +0.12%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to PRSMJOHNSN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check PRSMJOHNSN.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, HEIDELBERG.BO has a market cap of 32.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while HEIDELBERG.BO trades at ₹144.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas HEIDELBERG.BO's P/E ratio is 25.49. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to HEIDELBERG.BO's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to HEIDELBERG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check HEIDELBERG.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, HEIDELBERG.NS has a market cap of 32.6B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while HEIDELBERG.NS trades at ₹143.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas HEIDELBERG.NS's P/E ratio is 23.41. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to HEIDELBERG.NS's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to HEIDELBERG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check HEIDELBERG.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ORIENTCEM.BO has a market cap of 26B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ORIENTCEM.BO trades at ₹126.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ORIENTCEM.BO's P/E ratio is 8.02. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ORIENTCEM.BO's ROE of +0.17%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ORIENTCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ORIENTCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ORIENTCEM.NS has a market cap of 25.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ORIENTCEM.NS trades at ₹126.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ORIENTCEM.NS's P/E ratio is 8.00. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ORIENTCEM.NS's ROE of +0.17%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ORIENTCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ORIENTCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, MANGLMCEM.BO has a market cap of 21.7B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while MANGLMCEM.BO trades at ₹788.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas MANGLMCEM.BO's P/E ratio is 28.11. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to MANGLMCEM.BO's ROE of +0.09%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to MANGLMCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check MANGLMCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, MANGLMCEM.NS has a market cap of 21.5B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while MANGLMCEM.NS trades at ₹783.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas MANGLMCEM.NS's P/E ratio is 26.73. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to MANGLMCEM.NS's ROE of +0.09%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to MANGLMCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check MANGLMCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SAGCEM.NS has a market cap of 20.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SAGCEM.NS trades at ₹159.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SAGCEM.NS's P/E ratio is -12.50. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SAGCEM.NS's ROE of -0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SAGCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SAGCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SAGCEM.BO has a market cap of 20.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SAGCEM.BO trades at ₹159.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SAGCEM.BO's P/E ratio is -12.48. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SAGCEM.BO's ROE of -0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SAGCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SAGCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, EPACK.NS has a market cap of 20.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while EPACK.NS trades at ₹212.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas EPACK.NS's P/E ratio is 49.69. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to EPACK.NS's ROE of +0.04%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to EPACK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check EPACK.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, UDAICEMENT.NS has a market cap of 20.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while UDAICEMENT.NS trades at ₹36.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas UDAICEMENT.NS's P/E ratio is 201.28. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to UDAICEMENT.NS's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to UDAICEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check UDAICEMENT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, UDAICEMENT.BO has a market cap of 20.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while UDAICEMENT.BO trades at ₹36.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas UDAICEMENT.BO's P/E ratio is 201.06. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to UDAICEMENT.BO's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to UDAICEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check UDAICEMENT.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KCP.NS has a market cap of 16.5B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KCP.NS trades at ₹127.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KCP.NS's P/E ratio is 11.02. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KCP.NS's ROE of +0.09%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KCP.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KCP.BO has a market cap of 16.5B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KCP.BO trades at ₹127.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KCP.BO's P/E ratio is 10.99. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KCP.BO's ROE of +0.09%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KCP.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SANGHIIND.NS has a market cap of 12.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SANGHIIND.NS trades at ₹49.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SANGHIIND.NS's P/E ratio is -3.02. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SANGHIIND.NS's ROE of -0.69%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SANGHIIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SANGHIIND.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SANGHIIND.BO has a market cap of 12.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SANGHIIND.BO trades at ₹49.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SANGHIIND.BO's P/E ratio is -3.02. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SANGHIIND.BO's ROE of -0.69%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SANGHIIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SANGHIIND.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, IFGLEXPOR.BO has a market cap of 9.5B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while IFGLEXPOR.BO trades at ₹131.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas IFGLEXPOR.BO's P/E ratio is 32.86. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to IFGLEXPOR.BO's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to IFGLEXPOR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check IFGLEXPOR.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, IFGLEXPOR.NS has a market cap of 9.5B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while IFGLEXPOR.NS trades at ₹131.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas IFGLEXPOR.NS's P/E ratio is 32.91. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to IFGLEXPOR.NS's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to IFGLEXPOR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check IFGLEXPOR.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, APOLLOPIPES.BO has a market cap of 9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while APOLLOPIPES.BO trades at ₹686.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas APOLLOPIPES.BO's P/E ratio is 46.89. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to APOLLOPIPES.BO's ROE of +0.02%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to APOLLOPIPES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check APOLLOPIPES.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SHREDIGCEM.BO has a market cap of 8.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SHREDIGCEM.BO trades at ₹56.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SHREDIGCEM.BO's P/E ratio is 23.44. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SHREDIGCEM.BO's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SHREDIGCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SHREDIGCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SHREDIGCEM.NS has a market cap of 8.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SHREDIGCEM.NS trades at ₹56.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SHREDIGCEM.NS's P/E ratio is 23.37. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SHREDIGCEM.NS's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SHREDIGCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SHREDIGCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, DECCANCE.BO has a market cap of 8.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while DECCANCE.BO trades at ₹580.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas DECCANCE.BO's P/E ratio is 24.47. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to DECCANCE.BO's ROE of +0.04%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to DECCANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check DECCANCE.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, DECCANCE.NS has a market cap of 8.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while DECCANCE.NS trades at ₹576.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas DECCANCE.NS's P/E ratio is 25.37. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to DECCANCE.NS's ROE of +0.04%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to DECCANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check DECCANCE.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ORIRAIL.BO has a market cap of 7.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ORIRAIL.BO trades at ₹110.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ORIRAIL.BO's P/E ratio is 19.93. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ORIRAIL.BO's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ORIRAIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ORIRAIL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NCLIND.BO has a market cap of 7.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NCLIND.BO trades at ₹157.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NCLIND.BO's P/E ratio is 14.36. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NCLIND.BO's ROE of +0.07%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NCLIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NCLIND.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NCLIND.NS has a market cap of 7.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NCLIND.NS trades at ₹156.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NCLIND.NS's P/E ratio is 11.76. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NCLIND.NS's ROE of +0.07%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NCLIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NCLIND.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SAURASHCEM.NS has a market cap of 5.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SAURASHCEM.NS trades at ₹52.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SAURASHCEM.NS's P/E ratio is 20.46. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SAURASHCEM.NS's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SAURASHCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SAURASHCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SAURASHCEM.BO has a market cap of 5.8B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SAURASHCEM.BO trades at ₹52.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SAURASHCEM.BO's P/E ratio is 20.32. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SAURASHCEM.BO's ROE of +0.03%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SAURASHCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SAURASHCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SHIVACEM.BO has a market cap of 4.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SHIVACEM.BO trades at ₹13.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SHIVACEM.BO's P/E ratio is -2.80. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SHIVACEM.BO's ROE of -1.37%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SHIVACEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SHIVACEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ACL.NS has a market cap of 3.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ACL.NS trades at ₹42.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ACL.NS's P/E ratio is -2.35. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ACL.NS's ROE of -1.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ACL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ACL.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ACL.BO has a market cap of 3.9B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ACL.BO trades at ₹42.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ACL.BO's P/E ratio is -2.35. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ACL.BO's ROE of -1.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ACL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ACL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ZODIAC.BO has a market cap of 3.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ZODIAC.BO trades at ₹226.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ZODIAC.BO's P/E ratio is -53.73. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ZODIAC.BO's ROE of +0.21%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ZODIAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ZODIAC.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ZODIAC.NS has a market cap of 3.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ZODIAC.NS trades at ₹226.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ZODIAC.NS's P/E ratio is 60.61. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ZODIAC.NS's ROE of +0.21%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ZODIAC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ZODIAC.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NAVKAR.BO has a market cap of 3.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NAVKAR.BO trades at ₹14.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NAVKAR.BO's P/E ratio is 145.10. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NAVKAR.BO's ROE of -0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NAVKAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NAVKAR.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, APCL.NS has a market cap of 3.2B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while APCL.NS trades at ₹108.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas APCL.NS's P/E ratio is -7.77. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to APCL.NS's ROE of -0.18%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to APCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check APCL.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, APCL.BO has a market cap of 3.2B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while APCL.BO trades at ₹108.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas APCL.BO's P/E ratio is -7.76. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to APCL.BO's ROE of -0.18%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to APCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check APCL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, GSCLCEMENT.NS has a market cap of 3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while GSCLCEMENT.NS trades at ₹33.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas GSCLCEMENT.NS's P/E ratio is -87.37. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to GSCLCEMENT.NS's ROE of +0.04%. Regarding short-term risk, AMBUJACEM.NS is more volatile compared to GSCLCEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check GSCLCEMENT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KESORAMIND.BO has a market cap of 2.7B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KESORAMIND.BO trades at ₹8.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KESORAMIND.BO's P/E ratio is -1.88. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KESORAMIND.BO's ROE of +18.55%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KESORAMIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KESORAMIND.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KESORAMIND.NS has a market cap of 2.7B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KESORAMIND.NS trades at ₹8.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KESORAMIND.NS's P/E ratio is -1.87. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KESORAMIND.NS's ROE of +18.55%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KESORAMIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KESORAMIND.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SAHYADRI.NS has a market cap of 2.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SAHYADRI.NS trades at ₹217.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SAHYADRI.NS's P/E ratio is 10.50. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SAHYADRI.NS's ROE of +0.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SAHYADRI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SAHYADRI.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, SKCIL.BO has a market cap of 2.3B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while SKCIL.BO trades at ₹132.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas SKCIL.BO's P/E ratio is -200.38. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to SKCIL.BO's ROE of -0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to SKCIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check SKCIL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, GSLSU.NS has a market cap of 2.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while GSLSU.NS trades at ₹48.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas GSLSU.NS's P/E ratio is -11.06. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to GSLSU.NS's ROE of -0.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to GSLSU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check GSLSU.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, GSLSU.BO has a market cap of 2B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while GSLSU.BO trades at ₹48.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas GSLSU.BO's P/E ratio is -11.01. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to GSLSU.BO's ROE of -0.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to GSLSU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check GSLSU.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ASIIL.BO has a market cap of 2B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ASIIL.BO trades at ₹22.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ASIIL.BO's P/E ratio is 7.62. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ASIIL.BO's ROE of +0.08%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ASIIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ASIIL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BRPL.BO has a market cap of 1.6B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BRPL.BO trades at ₹119.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BRPL.BO's P/E ratio is 17.62. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BRPL.BO's ROE of +0.27%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BRPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BRPL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ALUWIND.NS has a market cap of 1.4B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ALUWIND.NS trades at ₹54.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ALUWIND.NS's P/E ratio is 12.53. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ALUWIND.NS's ROE of N/A. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ALUWIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ALUWIND.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, TRL.BO has a market cap of 1.1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while TRL.BO trades at ₹92.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas TRL.BO's P/E ratio is 27.58. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to TRL.BO's ROE of +0.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to TRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check TRL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NILACHAL.BO has a market cap of 1B. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NILACHAL.BO trades at ₹51.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NILACHAL.BO's P/E ratio is -4.31. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NILACHAL.BO's ROE of +1.06%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NILACHAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NILACHAL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KEIL.BO has a market cap of 964.6M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KEIL.BO trades at ₹11.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KEIL.BO's P/E ratio is -1131.00. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KEIL.BO's ROE of -0.00%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KEIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KEIL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, GLITTEKG.BO has a market cap of 921.3M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while GLITTEKG.BO trades at ₹35.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas GLITTEKG.BO's P/E ratio is 3.63. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to GLITTEKG.BO's ROE of +4.29%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to GLITTEKG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check GLITTEKG.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, RISHILASE.BO has a market cap of 911M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while RISHILASE.BO trades at ₹99.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas RISHILASE.BO's P/E ratio is 11.51. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to RISHILASE.BO's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to RISHILASE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check RISHILASE.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NAVKARURB.NS has a market cap of 852.8M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NAVKARURB.NS trades at ₹0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NAVKARURB.NS's P/E ratio is -10.86. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NAVKARURB.NS's ROE of +0.00%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NAVKARURB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NAVKARURB.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, NAVKARURB.BO has a market cap of 852.8M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while NAVKARURB.BO trades at ₹0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas NAVKARURB.BO's P/E ratio is -10.86. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to NAVKARURB.BO's ROE of +0.00%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to NAVKARURB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check NAVKARURB.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, PANCM.BO has a market cap of 833M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while PANCM.BO trades at ₹103.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas PANCM.BO's P/E ratio is -0.93. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to PANCM.BO's ROE of +0.39%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to PANCM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check PANCM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, PACIFICI.BO has a market cap of 832.3M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while PACIFICI.BO trades at ₹120.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas PACIFICI.BO's P/E ratio is 21.15. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to PACIFICI.BO's ROE of +0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to PACIFICI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check PACIFICI.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BVCL.BO has a market cap of 797.1M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BVCL.BO trades at ₹35.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BVCL.BO's P/E ratio is 3597.00. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BVCL.BO's ROE of +0.00%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BVCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BVCL.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BVCL.NS has a market cap of 788.5M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BVCL.NS trades at ₹35.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BVCL.NS's P/E ratio is 3558.00. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BVCL.NS's ROE of +0.00%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BVCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BVCL.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KAKATCEM.NS has a market cap of 691.1M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KAKATCEM.NS trades at ₹88.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KAKATCEM.NS's P/E ratio is -2.51. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KAKATCEM.NS's ROE of -0.13%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KAKATCEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KAKATCEM.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, KAKATCEM.BO has a market cap of 690.7M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while KAKATCEM.BO trades at ₹88.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas KAKATCEM.BO's P/E ratio is -2.54. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to KAKATCEM.BO's ROE of -0.13%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to KAKATCEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check KAKATCEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, REFRACTORY.NS has a market cap of 657.3M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while REFRACTORY.NS trades at ₹30.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas REFRACTORY.NS's P/E ratio is 10.85. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to REFRACTORY.NS's ROE of N/A. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to REFRACTORY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check REFRACTORY.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, CEETAIN.BO has a market cap of 598.9M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while CEETAIN.BO trades at ₹41.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas CEETAIN.BO's P/E ratio is 165.20. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to CEETAIN.BO's ROE of +0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to CEETAIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check CEETAIN.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, RESTILE.BO has a market cap of 591.6M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while RESTILE.BO trades at ₹6.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas RESTILE.BO's P/E ratio is -86.00. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to RESTILE.BO's ROE of +0.00%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to RESTILE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check RESTILE.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ELEMARB.BO has a market cap of 583.4M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ELEMARB.BO trades at ₹159.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ELEMARB.BO's P/E ratio is 13.26. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ELEMARB.BO's ROE of +0.02%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ELEMARB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ELEMARB.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BURNPUR.NS has a market cap of 568.4M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BURNPUR.NS trades at ₹33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BURNPUR.NS's P/E ratio is -0.21. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BURNPUR.NS's ROE of +0.10%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BURNPUR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BURNPUR.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, BHEEMACEM.BO has a market cap of 526.7M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while BHEEMACEM.BO trades at ₹16.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas BHEEMACEM.BO's P/E ratio is -1.56. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to BHEEMACEM.BO's ROE of -5.24%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to BHEEMACEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check BHEEMACEM.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, AHMDSTE.BO has a market cap of 503.5M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while AHMDSTE.BO trades at ₹123.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas AHMDSTE.BO's P/E ratio is 10.25. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to AHMDSTE.BO's ROE of +0.22%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to AHMDSTE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check AHMDSTE.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, DIVSHKT.BO has a market cap of 462.6M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while DIVSHKT.BO trades at ₹45.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas DIVSHKT.BO's P/E ratio is 31.95. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to DIVSHKT.BO's ROE of +0.01%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to DIVSHKT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check DIVSHKT.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ANDHRACEMT.NS has a market cap of 456.2M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ANDHRACEMT.NS trades at ₹4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ANDHRACEMT.NS's P/E ratio is -0.03. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ANDHRACEMT.NS's ROE of -0.20%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ANDHRACEMT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ANDHRACEMT.NS's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, MAYUKH.BO has a market cap of 432M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while MAYUKH.BO trades at ₹2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas MAYUKH.BO's P/E ratio is 56.25. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to MAYUKH.BO's ROE of +0.12%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to MAYUKH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check MAYUKH.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, PRATIK.BO has a market cap of 426.2M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while PRATIK.BO trades at ₹6.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas PRATIK.BO's P/E ratio is 29.00. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to PRATIK.BO's ROE of +0.23%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to PRATIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check PRATIK.BO's competition here

AMBUJACEM.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMBUJACEM.NS stands at 1T. In comparison, ZWELCAST.BO has a market cap of 421.3M. Regarding current trading prices, AMBUJACEM.NS is priced at ₹408.85, while ZWELCAST.BO trades at ₹660.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMBUJACEM.NS currently has a P/E ratio of 27.31, whereas ZWELCAST.BO's P/E ratio is -0.06. In terms of profitability, AMBUJACEM.NS's ROE is +0.06%, compared to ZWELCAST.BO's ROE of -0.17%. Regarding short-term risk, AMBUJACEM.NS is less volatile compared to ZWELCAST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMBUJACEM.NS.Check ZWELCAST.BO's competition here